Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q3 2014 · 10-Q
Revenue$275.06K$275.06K+607.0% vs Q3 2013 Net Income-$204.98K-$204.98KN/M vs Q3 2013 EPS Diluted-$0.01-$0.01— vs Q3 2013 Gross Profit$224,675+578.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$22,122N/M Margins · derivedGross margin81.7%−3.4 pt vs Q3 2013
Operating margin-190.1%+1209.1 pt vs Q3 2013
Net margin-74.5%+6728.5 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 14, 2014 · 45 d after period end